Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
IKT · NASDAQ · Biological Products, (No Diagnostic Substances)
$1.32+0.02 (+1.54%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Inhibikase Therapeutics (IKT) · oqro.io/stocks/IKT · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Everything reported about this company, newest first. Each line shows the dates that matter for its source.
Fund moves · Holdings as of Dec 31, 2025 (Q4 2025) · Filed Feb 13, 2026
Siren, L.L.C. disclosed a new position in IKT for Q4 2025SourceInsider trade · Traded Nov 21, 2025 · Filed Nov 24, 2025
10% owner purchased ~$3M of IKT shares in the open marketSourceFund moves · Holdings as of Jun 30, 2025 (Q2 2025) · Filed Aug 14, 2025
Perceptive Advisors LLC disclosed a reduced position in IKT for Q2 2025SourceFund moves · Holdings as of Dec 31, 2024 (Q4 2024) · Filed Feb 14, 2025
Perceptive Advisors LLC disclosed a new position in IKT for Q4 2024SourceInsider trade · Traded Oct 21, 2024 · Filed Oct 23, 2024
Director purchased ~$2M of IKT shares in the open marketSourceInsider trade · Traded Oct 21, 2024 · Filed Oct 23, 2024
Director purchased ~$500K of IKT shares in the open marketSourceInsider trade · Traded Oct 21, 2024 · Filed Oct 23, 2024
Director purchased ~$199K of IKT shares in the open marketSource